We are past the tipping point with the new oral anticoagulant drugs (NOACs), or direct oral anticoagulants (DOACs). Their dominance over warfarin has arrived. First is ease of use. These days everyone ...
Patients with diabetes and a history of atrial fibrillation (AF) have fewer diabetic complications and lower mortality rates when prescribed non-vitamin K antagonist oral anticoagulants (NOACs) rather ...
Recent use of non-vitamin K antagonist oral anticoagulants (NOACs) is not associated with increased risk for bleeding following treatment with intravenous alteplase for ischemic stroke, new data ...
Thromboembol in blood vessel. Clot formation, 3D illustration Experts review the current indications for NOACs as well as research on use as venous thromboembolism (VTE) prophylaxis in patients with ...
LISBON, Portugal—For patients with nonvalvular A-fib, one of the major selling points for use of non-vitamin K antagonist oral anticoagulants (NOACs) over warfarin for stroke prophylaxis has been that ...
A retrospective cohort study of patients with atrial fibrillation and diabetes found that the use of non–vitamin K antagonist oral anticoagulants (NOAC) was associated with a lower risk of diabetes ...
Results from the FRAIL-AF study, being presented at the European Society of Cardiology 2023 Congress, surprised the investigators. In a study that will likely turn heads among cardiologists, findings ...
Non-vitamin K oral anticoagulants reduce hemorrhagic stroke and intracranial hemorrhage risks vs vitamin K antagonists in patients with end-stage renal disease and atrial fibrillation. Non-vitamin K ...
Long-term outcomes with left atrial appendage (LAA) closure have been holding steady as compared with anticoagulation, the PRAGUE-17 trial affirmed, although without answering questions about late ...
Switching vitamin K antagonist (VKA) treatment to a non-vitamin K antagonist oral anticoagulant (NOAC) in frail elderly patients with atrial fibrillation is associated with more bleeding complications ...
A suggested benefit of the non-vitamin K antagonist oral anticoagulants (NOACs) is that they have fewer drug–drug interactions than warfarin. However, according to a retrospective cohort study ...
The use of NOACs expanded quickly into treatment and prophylaxis for recurrent VTE and prophylaxis of VTE following hip and knee replacement surgery. The dosing for this indication is different from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results